MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 02-21-2026
BeyondSpring Retained Earnings 2011-2026 | BYSI
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings BeyondSpring
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -407 M | -396 M | -375 M | -342 M | -278 M | -217 M | -179 M | -124 M | -32.1 M | -20.1 M | -12.1 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.1 M | -407 M | -217 M |
Quarterly Retained Earnings BeyondSpring
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -406 M | -405 M | -403 M | -407 M | - | - | - | - | - | - | - | -342 M | -332 M | -314 M | -295 M | -278 M | -260 M | -246 M | -233 M | -217 M | -203 M | -193 M | -186 M | -179 M | - | -150 M | -138 M | -124 M | -108 M | -92.9 M | -79.5 M | -32.1 M | - | - | - | -20.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -20.1 M | -407 M | -226 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-972 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 163.89 | - | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
-3.82 B | $ 64.28 | -3.31 % | $ 12.3 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
-152 M | $ 1.37 | 5.81 % | $ 29 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.82 | -0.35 % | $ 908 M |  Israel |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 59.8 | -3.13 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
16.9 B | $ 62.08 | -0.46 % | $ 126 B | USA |
 |
Benitec Biopharma
BNTC
|
-228 M | $ 10.93 | 0.23 % | $ 450 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 109.33 | -0.82 % | $ 27.2 B | Germany |
 |
Black Diamond Therapeutics
BDTX
|
-487 M | $ 2.38 | -3.44 % | $ 131 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-650 M | $ 1.63 | -2.4 % | $ 4.13 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
-233 M | $ 3.34 | 0.61 % | $ 3.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 4.88 | 2.74 % | $ 10.6 B | Israel |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Capricor Therapeutics
CAPR
|
-159 M | $ 27.28 | -2.32 % | $ 731 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 11.67 | -3.47 % | $ 768 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
C4 Therapeutics
CCCC
|
-739 M | $ 3.06 | 13.3 % | $ 254 M | USA |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Athira Pharma
ATHA
|
-406 M | - | - | $ 269 M | USA |
 |
Codexis
CDXS
|
-563 M | $ 0.99 | -2.04 % | $ 72.7 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |